Trial Profile
A Multicenter, Controlled, Open-Label Extension (OLE) Study To Assess the Long-Term Safety and Efficacy of Evolocumab (AMG 145)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms OSLER; OSLER-1; PROFICIO
- Sponsors Amgen
- 29 Oct 2019 Results evaluating long-term efficacy and safety of Evolocumab in patients With Hypercholesterolemia published in the Journal of the American College of Cardiology
- 29 Mar 2019 Results (n=556) evaluating safety and efficacy results of evolocumab in japanese patients of the OSLER studies published in the Circulation Journal
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association